Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1981 Apr;19(4):575–577. doi: 10.1128/aac.19.4.575

Moxalactam pharmacokinetics during hemodialysis.

G R Aronoff, R S Sloan, S A Mong, F C Luft, S A Kleit
PMCID: PMC181480  PMID: 6454386

Abstract

To establish dosage recommendations, moxalactam elimination kinetics were studied in six anephric patients during hemodialysis and in four anephric patients during the interdialytic period. After a single 1-g intravenous bolus injection, moxalactam elimination half-life was 18.0 plus or minus 0.6 h with a volume of distribution of 20.2 plus or minus 3.6 liters and a plasma clearance of 12.8 plus or minus 2.0 ml/min in four nondialyzed patients. Moxalactam elimination half-life was decreased to 2.7 plus or minus 0.2 h during hemodialysis in six patients. After 4 h, 48.5% of the dose was recovered in the dialysate. The maintenance dose of moxalactam should be decreased to 15% of a normal dose in patients with creatinine clearances less than 10 ml/min, and 50% of a loading dose should be given after hemodialysis.

Full text

PDF
575

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Borobio M. V., Aznar J., Jimenez R., Garcia F., Perea E. J. Comparative in vitro activity of 1-oxa-beta-lactam (LY127935) and cefoperazone with other beta-lactam antibiotics against anaerobic bacteria. Antimicrob Agents Chemother. 1980 Feb;17(2):129–131. doi: 10.1128/aac.17.2.129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Gibson T. P., Matusik E., Nelson L. D., Briggs W. A. Artificial kidneys and clearance calculations. Clin Pharmacol Ther. 1976 Dec;20(6):720–726. doi: 10.1002/cpt1976206720. [DOI] [PubMed] [Google Scholar]
  3. Greenblatt D. J., Kock-Weser J. Drug therapy. Clinical Pharmacokinetics (first of two parts). N Engl J Med. 1975 Oct 2;293(14):702–705. doi: 10.1056/NEJM197510022931406. [DOI] [PubMed] [Google Scholar]
  4. Jones R. N., Fuchs P. C., Sommers H. M., Gavan T. L., Barry A. L., Gerlach E. H. Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin. Antimicrob Agents Chemother. 1980 Apr;17(4):750–756. doi: 10.1128/aac.17.4.750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Lee C. S., Marbury T. C., Benet L. Z. Clearance calculations in hemodialysis: application to blood, plasma, and dialysate measurements for ethambutol. J Pharmacokinet Biopharm. 1980 Feb;8(1):69–81. doi: 10.1007/BF01059449. [DOI] [PubMed] [Google Scholar]
  6. Parsons J. N., Romano J. M., Levison M. E. Pharmacology of a new 1-oxa-beta-lactam (LY127935) in normal volunteers. Antimicrob Agents Chemother. 1980 Feb;17(2):226–228. doi: 10.1128/aac.17.2.226. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES